Literature DB >> 33835888

Acute disseminated encephalomyelitis and routine childhood vaccinations - a self-controlled case series.

T J Martin1,2,3,4, M Fahey1,4, M Easton2, H J Clothier2,5, R Samuel1, N W Crawford2,3,6, J P Buttery1,2,3,4,6.   

Abstract

Acute disseminated encephalomyelitis (ADEM) is an autoimmune, central nervous system demyelinating disorder that follows antecedent immunologic challenges, such as infection or vaccination. This study aimed to investigate the potential association between routine childhood vaccinations and ADEM. Children under 7 years of age admitted to the two tertiary level pediatric hospitals in Victoria, Australia with ADEM from 2000-2015 had their clinical information linked to vaccination records from the Australian Childhood Immunization Register. Chart review was undertaken utilizing the Brighton Collaboration ADEM criteria. The self-controlled case-series (SCCS) methodology was employed to determine the relative incidences of ADEM post-vaccination in two risk intervals: 5-28 days and 2-42 days. Forty-six cases were eligible for SCCS analysis with a median age of 3.2 years. Of the forty-six cases, three were vaccine proximate cases and received vaccinations 23, 25 and 28 days before ADEM onset. Two vaccine proximate cases received their 4-year-old scheduled vaccinations (MMR and DTPa-IPV) and one vaccine proximate case the 1-year old scheduled vaccinations (MMR and Hib-MenC). The relative incidence of ADEM during the narrow and broad risk intervals were 1.041 (95% CI 0.323-3.356, p = 0.946) and 0.585 (95% CI 0.182-1.886, p = 0.370) respectively. Sensitivity analyses did not yield any substantial deviations. These results do not provide evidence of an association between vaccinations routinely provided to children aged under 7 years in Australia and the incidence of ADEM. However, these results should be interpreted with caution as the number of ADEM cases identified was limited and further research is warranted.

Entities:  

Keywords:  Acute disseminated encephalomyelitis; adverse event; immunization; self-controlled case series; vaccination; vaccine

Mesh:

Substances:

Year:  2021        PMID: 33835888      PMCID: PMC8475584          DOI: 10.1080/21645515.2021.1901544

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  48 in total

Review 1.  Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.

Authors:  Frederick Varricchio; John Iskander; Frank Destefano; Robert Ball; Robert Pless; M Miles Braun; Robert T Chen
Journal:  Pediatr Infect Dis J       Date:  2004-04       Impact factor: 2.129

2.  Febrile convulsions after 2010 seasonal trivalent influenza vaccine: implications for vaccine safety surveillance in Australia.

Authors:  Michael S Gold; Paul Effler; Heath Kelly; Peter C Richmond; Jim P Buttery
Journal:  Med J Aust       Date:  2010-11-01       Impact factor: 7.738

3.  Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004.

Authors:  Tetsuo Nakayama; Kazumasa Onoda
Journal:  Vaccine       Date:  2006-08-04       Impact factor: 3.641

Review 4.  Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice.

Authors:  Y G Weldeselassie; H J Whitaker; C P Farrington
Journal:  Epidemiol Infect       Date:  2011-08-18       Impact factor: 2.451

Review 5.  Immune-mediated CNS diseases: a review on nosological classification and clinical features.

Authors:  Uwe K Zettl; Olaf Stüve; Robert Patejdl
Journal:  Autoimmun Rev       Date:  2011-05-18       Impact factor: 9.754

6.  Acute disseminated encephalomyelitis: a long-term prospective study and meta-analysis.

Authors:  P Pavone; M Pettoello-Mantovano; A Le Pira; I Giardino; A Pulvirenti; R Giugno; E Parano; A Polizzi; A Distefano; A Ferro; L Pavone; M Ruggieri
Journal:  Neuropediatrics       Date:  2011-03-28       Impact factor: 1.947

7.  Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine.

Authors:  Barbara A Pahud; Carol A Glaser; Cornelia L Dekker; Ann M Arvin; D Scott Schmid
Journal:  J Infect Dis       Date:  2010-12-21       Impact factor: 5.226

8.  Acute disseminated encephalomyelitis in children. A descriptive study in Tehran, Iran.

Authors:  Noorbakhsh Samile; Tonekaboni Hassan
Journal:  Saudi Med J       Date:  2007-03       Impact factor: 1.484

9.  Acute disseminated encephalomyelitis in childhood: epidemiologic, clinical and laboratory features.

Authors:  John A D Leake; Salvatore Albani; Annie S Kao; Melvin O Senac; Glenn F Billman; Mark P Nespeca; Amy D Paulino; Eileen R Quintela; Mark H Sawyer; John S Bradley
Journal:  Pediatr Infect Dis J       Date:  2004-08       Impact factor: 2.129

10.  Acute disseminated encephalomyelitis in children: clinical features and HLA-DR linkage.

Authors:  Zh R Idrissova; M N Boldyreva; E P Dekonenko; N A Malishev; I Y Leontyeva; I N Martinenko; A S Petrukhin
Journal:  Eur J Neurol       Date:  2003-09       Impact factor: 6.089

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.